Actinium Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ATNM, Actinium Pharmaceuticals Inc, priceseries

Actinium Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.99
Close
4.87
High
5.08
Low
4.79
Previous Close
4.97
Daily Price Gain
-0.10
YTD High
6.48
YTD High Date
Jan 4, 2022
YTD Low
4.53
YTD Low Date
Feb 24, 2022
YTD Price Change
-1.53
YTD Gain
-23.91%
52 Week High
10.30
52 Week High Date
Sep 24, 2021
52 Week Low
4.53
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-3.01
52 Week Gain
-38.20%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 13. 2018
14.25
Jun 28. 2018
17.34
11 Trading Days
21.67%
Link
LONG
Jul 11. 2018
20.09
Jul 26. 2018
21.82
11 Trading Days
8.57%
Link
LONG
Sep 12. 2018
19.83
Oct 10. 2018
23.28
20 Trading Days
17.41%
Link
LONG
Nov 27. 2019
6.84
Dec 5. 2019
7.27
5 Trading Days
6.33%
Link
LONG
Jun 3. 2020
6.64
Jun 17. 2020
10.44
10 Trading Days
57.12%
Link
LONG
Jun 22. 2020
13.20
Jun 23. 2020
13.92
1 Trading Days
5.45%
Link
LONG
Jul 16. 2020
11.00
Aug 5. 2020
15.88
14 Trading Days
44.39%
Link
LONG
Sep 11. 2020
8.52
Sep 23. 2020
9.02
8 Trading Days
5.86%
Link
LONG
Oct 5. 2020
9.60
Oct 20. 2020
10.98
11 Trading Days
14.34%
Link
LONG
Feb 1. 2021
8.29
Feb 10. 2021
8.85
7 Trading Days
6.80%
Link
Company Information
Stock Symbol
ATNM
Exchange
NYSE MKT
Company URL
http://www.actiniumpharmaceuticals.com
Company Phone
646-677-3875
CEO
Kaushik J. Dave
Headquarters
New York
Business Address
275 MADISON AVENUE, 7TH FLOOR, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001388320
About

Actinium Pharmaceuticals, Inc. operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers. It targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company was founded in 1993 and is headquartered in New York, NY.

Description

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading